LRRK2 and Parkinson disease: To determine whether iron also accumulates in PD patients due to the G2019S-LRRK2 mutation as compared to healthy age-matched controls (Table 1), we measured total iron and other trace metal content in distinct brain areas by inductively coupled plasma mass spectrometry (ICP-MS).